{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:16:18Z","timestamp":1791490578995,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lab Anim"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41684-024-01504-1","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T10:04:40Z","timestamp":1738231480000},"page":"42-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A comparative review of murine models of repeated low-dose cisplatin-induced chronic kidney disease"],"prefix":"10.1038","volume":"54","author":[{"given":"Hong-Wei","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8404-8241","authenticated-orcid":false,"given":"Cai-Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"1504_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41581-022-00631-7","volume":"19","author":"C Tang","year":"2023","unstructured":"Tang, C., Livingston, M. J., Safirstein, R. & Dong, Z. Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat. Rev. Nephrol. 19, 53\u201372 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1504_CR2","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/cancers13071572","volume":"13","author":"KR McSweeney","year":"2021","unstructured":"McSweeney, K. R. et al. Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers 13, 1572 (2021).","journal-title":"Cancers"},{"key":"1504_CR3","doi-asserted-by":"publisher","first-page":"e0142225","DOI":"10.1371\/journal.pone.0142225","volume":"10","author":"ZY Bhat","year":"2015","unstructured":"Bhat, Z. Y. et al. Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study. PLoS ONE 10, e0142225 (2015).","journal-title":"PLoS ONE"},{"key":"1504_CR4","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1002\/cam4.4715","volume":"11","author":"NS Menon","year":"2022","unstructured":"Menon, N. S. et al. Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin. Cancer Med 11, 3939\u20133948 (2022).","journal-title":"Cancer Med"},{"key":"1504_CR5","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.21.01293","volume":"40","author":"N Kiyota","year":"2022","unstructured":"Kiyota, N. et al. Weekly cisplatin plus radiation for postoperative head and neck cancer (jcog1008): a multicenter, noninferiority, phase II\/III randomized controlled trial. J. Clin. Oncol. 40, 1980\u20131990 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1504_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100351","volume":"7","author":"S Suppadungsuk","year":"2022","unstructured":"Suppadungsuk, S. et al. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study). ESMO Open 7, 100351 (2022).","journal-title":"ESMO Open"},{"key":"1504_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.103022","volume":"70","author":"KA Mapuskar","year":"2024","unstructured":"Mapuskar, K. A. et al. The antioxidant and anti-inflammatory activities of avasopasem manganese in age-associated, cisplatin-induced renal injury. Redox Biol. 70, 103022 (2024).","journal-title":"Redox Biol."},{"key":"1504_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102599","volume":"60","author":"KA Mapuskar","year":"2023","unstructured":"Mapuskar, K. A. et al. Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: an exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients. Redox Biol. 60, 102599 (2023).","journal-title":"Redox Biol."},{"key":"1504_CR9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1681\/ASN.2020101455","volume":"32","author":"SM Sears","year":"2021","unstructured":"Sears, S. M. & Siskind, L. J. Potential therapeutic targets for cisplatin-induced kidney injury: lessons from other models of AKI and fibrosis. J. Am. Soc. Nephrol. 32, 1559\u20131567 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1504_CR10","doi-asserted-by":"publisher","unstructured":"Qiu, C.-W., Chen, B., Zhu, H.-F., Liang, Y.-L. & Mao, L.-S. Gastrodin alleviates cisplatin nephrotoxicity by inhibiting ferroptosis via the SIRT1\/FOXO3A\/GPX4 signaling pathway. J. Ethnopharmacol. https:\/\/doi.org\/10.1016\/j.jep.2023.117282 (2024).","DOI":"10.1016\/j.jep.2023.117282"},{"key":"1504_CR11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1681\/ASN.2016030337","volume":"28","author":"D Zhang","year":"2017","unstructured":"Zhang, D. et al. Protein kinase C\u03b4 suppresses autophagy to induce kidney cell apoptosis in cisplatin nephrotoxicity. J. Am. Soc. Nephrol. 28, 1131\u20131144 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1504_CR12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41374-018-0063-2","volume":"98","author":"M Shi","year":"2018","unstructured":"Shi, M. et al. Cisplatin nephrotoxicity as a model of chronic kidney disease. Lab Invest. 98, 1105\u20131121 (2018).","journal-title":"Lab Invest."},{"key":"1504_CR13","doi-asserted-by":"publisher","first-page":"F560","DOI":"10.1152\/ajprenal.00512.2015","volume":"310","author":"CN Sharp","year":"2016","unstructured":"Sharp, C. N. et al. Repeated administration of low-dose cisplatin in mice induces fibrosis. Am. J. Physiol. Renal Physiol. 310, F560\u2013F568 (2016).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1504_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.kint.2019.04.031","volume":"96","author":"LA Balmer","year":"2019","unstructured":"Balmer, L. A. et al. Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease. Kidney Int. 96, 918\u2013926 (2019).","journal-title":"Kidney Int."},{"key":"1504_CR15","doi-asserted-by":"publisher","first-page":"F1582","DOI":"10.1152\/ajprenal.00385.2019","volume":"317","author":"Y Fu","year":"2019","unstructured":"Fu, Y. et al. Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys and renal tubular cells. Am. J. Physiol. Renal Physiol. 317, F1582\u2013f1592 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1504_CR16","doi-asserted-by":"publisher","first-page":"F674","DOI":"10.1152\/ajprenal.00196.2020","volume":"319","author":"SM Sears","year":"2020","unstructured":"Sears, S. M. et al. C57BL\/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury. Am. J. Physiol. Renal Physiol. 319, F674\u2013F685 (2020).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1504_CR17","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1096\/fj.201901412R","volume":"34","author":"H Su","year":"2020","unstructured":"Su, H. et al. Subcellular trafficking of tubular MDM2 implicates in acute kidney injury to chronic kidney disease transition during multiple low-dose cisplatin exposure. FASEB J. 34, 1620\u20131636 (2020).","journal-title":"FASEB J."},{"key":"1504_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623693","volume":"11","author":"L Wu","year":"2020","unstructured":"Wu, L. et al. Bone marrow mesenchymal stem cells ameliorate cisplatin-induced renal fibrosis via miR-146a-5p\/Tfdp2 axis in renal tubular epithelial cells. Front. Immunol. 11, 623693 (2020).","journal-title":"Front. Immunol."},{"key":"1504_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00392-6","volume":"11","author":"N Yamashita","year":"2021","unstructured":"Yamashita, N. et al. Cumulative DNA damage by repeated low-dose cisplatin injection promotes the transition of acute to chronic kidney injury in mice. Sci. Rep. 11, 20920 (2021).","journal-title":"Sci. Rep."},{"key":"1504_CR20","doi-asserted-by":"publisher","first-page":"F835","DOI":"10.1152\/ajprenal.00285.2017","volume":"313","author":"CN Sharp","year":"2017","unstructured":"Sharp, C. N. & Siskind, L. J. Developing better mouse models to study cisplatin-induced kidney injury. Am. J. Physiol. Renal Physiol. 313, F835\u2013f841 (2017).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1504_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.freeradbiomed.2018.11.006","volume":"130","author":"C Li","year":"2019","unstructured":"Li, C. et al. N-acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through sirtuin1 activation and p53 deacetylation. Free Radic. Biol. Med. 130, 512\u2013527 (2019).","journal-title":"Free Radic. Biol. Med."},{"key":"1504_CR22","doi-asserted-by":"publisher","first-page":"e166643","DOI":"10.1172\/jci.insight.166643","volume":"8","author":"S Li","year":"2023","unstructured":"Li, S. et al. Tubular cell senescence promotes maladaptive kidney repair and chronic kidney disease after cisplatin nephrotoxicity. JCI Insight 8, e166643 (2023).","journal-title":"JCI Insight"},{"key":"1504_CR23","doi-asserted-by":"publisher","first-page":"F161","DOI":"10.1152\/ajprenal.00636.2017","volume":"315","author":"CN Sharp","year":"2018","unstructured":"Sharp, C. N. et al. Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease. Am. J. Physiol. Renal Physiol. 315, F161\u2013f172 (2018).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1504_CR24","doi-asserted-by":"publisher","first-page":"F288","DOI":"10.1152\/ajprenal.00097.2022","volume":"323","author":"SM Sears","year":"2022","unstructured":"Sears, S. M. et al. Pharmacological inhibitors of autophagy have opposite effects in acute and chronic cisplatin-induced kidney injury. Am. J. Physiol. Renal Physiol. 323, F288\u2013F298 (2022).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1504_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112701","volume":"147","author":"YS Tsai","year":"2022","unstructured":"Tsai, Y. S. et al. Lactobacillus rhamnosus GKLC1 ameliorates cisplatin-induced chronic nephrotoxicity by inhibiting cell inflammation and apoptosis. Biomed. Pharmacother. 147, 112701 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1504_CR26","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1681\/ASN.2021040439","volume":"33","author":"X Guo","year":"2022","unstructured":"Guo, X. et al. Kidney-targeted renalase agonist prevents cisplatin-induced chronic kidney disease by inhibiting regulated necrosis and inflammation. J. Am. Soc. Nephrol. 33, 342\u2013356 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1504_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.redox.2018.09.020","volume":"20","author":"KA Mapuskar","year":"2019","unstructured":"Mapuskar, K. A. et al. Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. Redox Biol. 20, 98\u2013106 (2019).","journal-title":"Redox Biol."},{"key":"1504_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.kint.2018.11.042","volume":"95","author":"SI Landau","year":"2019","unstructured":"Landau, S. I. et al. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease. Kidney Int. 95, 797\u2013814 (2019).","journal-title":"Kidney Int."},{"key":"1504_CR29","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1681\/ASN.2016040454","volume":"27","author":"VD Garovic","year":"2016","unstructured":"Garovic, V. D. & August, P. Sex differences and renal protection: keeping in touch with your feminine side. J. Am. Soc. Nephrol. 27, 2921\u20132924 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1504_CR30","doi-asserted-by":"publisher","first-page":"F740","DOI":"10.1152\/ajprenal.00049.2017","volume":"313","author":"R Boddu","year":"2017","unstructured":"Boddu, R. et al. Unique sex- and age-dependent effects in protective pathways in acute kidney injury. Am. J. Physiol. Renal Physiol. 313, F740\u2013f755 (2017).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1504_CR31","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.7150\/thno.81406","volume":"13","author":"Y Fu","year":"2023","unstructured":"Fu, Y. et al. The STAT1\/HMGB1\/NF-\u03baB pathway in chronic inflammation and kidney injury after cisplatin exposure. Theranostics 13, 2757\u20132773 (2023).","journal-title":"Theranostics"},{"key":"1504_CR32","doi-asserted-by":"crossref","unstructured":"Shi, G. et al. RB\/T 173-2018. Guidelines of Assessment for Humane Endpoints in Animal Experiment (National Certification and Accreditation Administration, 2018).","DOI":"10.1016\/B978-0-12-805070-5.00017-5"},{"key":"1504_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/0023677219883319","volume":"54","author":"SR Talbot","year":"2020","unstructured":"Talbot, S. R. et al. Defining body-weight reduction as a humane endpoint: a critical appraisal. Lab. Anim. 54, 99\u2013110 (2020).","journal-title":"Lab. Anim."},{"key":"1504_CR34","unstructured":"Morton, D. B. Humane endpoints in animal experimentation for biomedical research: ethical, legal and practical aspects. In Humane Endpoints in Animal Experiments for Biomedical Research (eds Hendriksen, C. F. M. & Morton, D. B.) 5\u201312 (The Royal Society Medical Press, 1998)."},{"key":"1504_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120845","volume":"306","author":"EG El-Waseif","year":"2022","unstructured":"El-Waseif, E. G., Sharawy, M. H. & Suddek, G. M. The modulatory effect of sodium molybdate against cisplatin-induced CKD: role of TGF-\u03b2\/Smad signaling pathway. Life Sci. 306, 120845 (2022).","journal-title":"Life Sci."},{"key":"1504_CR36","doi-asserted-by":"publisher","first-page":"6636","DOI":"10.3390\/ijms24076636","volume":"24","author":"Z Xing","year":"2023","unstructured":"Xing, Z., Gong, K., Hu, N. & Chen, Y. The reduction of uromodulin, complement factor H, and their interaction is associated with acute kidney injury to chronic kidney disease transition in a four-time cisplatin-injected rat model. Int. J. Mol. Sci. 24, 6636 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1504_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.124985","volume":"242","author":"AA Shati","year":"2023","unstructured":"Shati, A. A. et al. Comparison of the ameliorative roles of crab chitosan nanoparticles and mesenchymal stem cells against cisplatin-triggered nephrotoxicity. Int. J. Biol. Macromol. 242, 124985 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"1504_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00210-020-01976-1","volume":"394","author":"M Al Za\u2019abi","year":"2021","unstructured":"Al Za\u2019abi, M. et al. Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats. Naunyn Schmiedebergs Arch. Pharmacol. 394, 249\u2013259 (2021).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"1504_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12906-023-04068-8","volume":"23","author":"A Gholami","year":"2023","unstructured":"Gholami, A. et al. The ameliorating effect of Limosilactobacillus fermentum and its supernatant postbiotic on cisplatin-induced chronic kidney disease in an animal model. BMC Complement. Med. Ther. 23, 243 (2023).","journal-title":"BMC Complement. Med. Ther."}],"container-title":["Lab Animal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41684-024-01504-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-024-01504-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-024-01504-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T13:58:59Z","timestamp":1738591139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41684-024-01504-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1038\/s41684-024-01504-1","relation":{},"ISSN":["0093-7355","1548-4475"],"issn-type":[{"value":"0093-7355","type":"print"},{"value":"1548-4475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}